首页> 外文期刊>Cancer chemotherapy and pharmacology. >Evaluating primary intra-arterial chemotherapy versus intravenous plus intra-arterial chemotherapy for advanced intraocular retinoblastoma
【24h】

Evaluating primary intra-arterial chemotherapy versus intravenous plus intra-arterial chemotherapy for advanced intraocular retinoblastoma

机译:评估初级动脉内化疗与静脉内静脉内碱基碱基,用于高级眼内视网膜母细胞瘤

获取原文
获取原文并翻译 | 示例

摘要

Purpose Although intra-arterial chemotherapy (IAC) is commonly used for treating intraocular retinoblastoma, it is not a systemic therapy. We aimed to investigate whether the addition of intravenous chemotherapy (IVC) before IAC administration had any effects (whether beneficial or adverse) on patient outcomes. Methods This multicenter retrospective cohort study included 213 patients with advanced intraocular retinoblastoma who received IVC plus IAC (n = 103) or IAC alone (n = 110) between April 2009 and January 2017. Eyes were grouped according to the International Intraocular Retinoblastoma Classification. Kaplan-Meier and Cox regression analyses were performed to compare survival outcomes between the two groups. Moreover, details regarding enucleation were recorded. Results The 3-year ocular survival rates were 62% in the IVC plus IAC group and 68% in the IAC group (hazard ratio (HR) 0.88, 95% confidence interval (CI) 0.55-1.43, P = 0.61). Moreover, the corresponding 3-year overall survival rates were 97% and 93%, respectively (HR 1.56, 95% CI 0.41-5.90, P = 0.51), while the 3-year event-free survival rates were 76% and 72%, respectively (HR 0.96, 95% CI 0.56-1.65, P = 0.89). Conclusions Within a 3-year follow-up period, IVC plus IAC produced no additional benefit over primary IAC for treating advanced intraocular retinoblastoma in terms of local tumor control and extending survival. Longer follow-up periods are required to assess long-term efficacy.
机译:目的虽然动脉内化疗(IAC)通常用于治疗眼内视网膜母细胞瘤,但它不是一种全身性治疗。我们的目的是调查在IAC给药前增加静脉化疗(IVC)是否对患者预后有任何影响(无论是有益的还是有害的)。方法这项多中心回顾性队列研究包括213例晚期眼内视网膜母细胞瘤患者,他们在2009年4月至2017年1月期间接受IVC加IAC(n=103)或单独IAC(n=110)。根据国际眼内视网膜母细胞瘤分类对眼睛进行分组。Kaplan-Meier和Cox回归分析用于比较两组之间的生存结果。此外,还记录了眼球摘除术的细节。结果IVC加IAC组3年生存率为62%,IAC组为68%(危险比(HR)0.88,95%可信区间(CI)0.55-1.43,P=0.61)。此外,相应的3年总生存率分别为97%和93%(HR 1.56,95%CI 0.41-5.90,P=0.51),而3年无事件生存率分别为76%和72%(HR 0.96,95%CI 0.56-1.65,P=0.89)。结论在3年的随访期内,IVC加IAC治疗晚期眼内视网膜母细胞瘤在局部肿瘤控制和延长生存期方面没有比原发IAC产生额外的益处。评估长期疗效需要更长的随访期。

著录项

  • 来源
  • 作者单位

    Jinan Univ Dept Radiol Affiliated Hosp 1 613 Huangpu West Rd Guangzhou 510627 Guangdong;

    Jinan Univ Dept Radiol Affiliated Hosp 1 613 Huangpu West Rd Guangzhou 510627 Guangdong;

    Guangdong Acad Med Sci Dept Radiol Guangdong Gen Hosp Guangzhou Guangdong Peoples R China;

    Jinan Univ Dept Radiol Affiliated Hosp 1 613 Huangpu West Rd Guangzhou 510627 Guangdong;

    Jinan Univ Dept Radiol Affiliated Hosp 1 613 Huangpu West Rd Guangzhou 510627 Guangdong;

    Guangzhou Women &

    Childrens Med Ctr Dept Intervent Radiol &

    Vasc Anomalies 9 Jinsui Rd Guangzhou;

    Guangzhou Women &

    Childrens Med Ctr Dept Intervent Radiol &

    Vasc Anomalies 9 Jinsui Rd Guangzhou;

    Jinan Univ Dept Radiol Affiliated Hosp 1 613 Huangpu West Rd Guangzhou 510627 Guangdong;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药理学;
  • 关键词

    Advanced retinoblastoma; Intravenous chemotherapy; Intra-arterial chemotherapy; Survival outcomes;

    机译:先进的视网膜细胞瘤;静脉化疗;动脉内化疗;生存结果;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号